Zemuron

Zemuron is a brand name of rocuronium, approved by the FDA in the following formulation(s):

ZEMURON (rocuronium bromide - injectable; injection)

• 
  Manufacturer: SCHERING
  
  Approval date: March 17, 1994
  
  Strength(s): 100MG/10ML (10MG/ML) ^[RLD][AP], 50MG/5ML (10MG/ML) ^[RLD][AP]

Has a generic version of Zemuron been approved?

A generic version of Zemuron has been approved by the FDA. However, this does not mean that the product will necessarily be commercially available - possibly because of drug patents and/or drug exclusivity. The following products are equivalent to Zemuron and have been approved by the FDA:

rocuronium bromide injectable; injection

• 
  Manufacturer: APP PHARMS
  
  Approval date: December 29, 2008
  
  Strength(s): 100MG/10ML (10MG/ML) ^[AP], 50MG/5ML (10MG/ML) ^[AP]


• 
  Manufacturer: BIONICHE PHARMA USA
  
  Approval date: November 26, 2008
  
  Strength(s): 100MG/10ML (10MG/ML) ^[AP], 50MG/5ML (10MG/ML) ^[AP]


• 
  Manufacturer: HOSPIRA
  
  Approval date: November 26, 2008
  
  Strength(s): 100MG/10ML (10MG/ML) ^[AP], 50MG/5ML (10MG/ML) ^[AP]


• 
  Manufacturer: SAGENT STRIDES
  
  Approval date: July 28, 2010
  
  Strength(s): 100MG/10ML (10MG/ML) ^[AP], 50MG/5ML (10MG/ML) ^[AP]


• 
  Manufacturer: SANDOZ
  
  Approval date: December 5, 2008
  
  Strength(s): 100MG/10ML (10MG/ML) ^[AP], 50MG/5ML (10MG/ML) ^[AP]


• 
  Manufacturer: TEVA PARENTERAL
  
  Approval date: November 26, 2008
  
  Strength(s): 100MG/10ML (10MG/ML) ^[AP], 50MG/5ML (10MG/ML) ^[AP]

Note: Fraudulent online pharmacies may attempt to sell an illegal generic version of Zemuron. These medications may be counterfeit and potentially unsafe. If you purchase medications online, be sure you are buying from a reputable and valid online pharmacy. Ask your health care provider for advice if you are unsure about the online purchase of any medication.

See also: About generic drugs.

Related Patents

There are no current U.S. patents associated with Zemuron.

Related Exclusivities

Exclusivity is exclusive marketing rights granted by the FDA upon approval of a drug and can run concurrently with a patent or not. Exclusivity is a statutory provision and is granted to an NDA applicant if statutory requirements are met.

• Exclusivity expiration dates:
  • August 28, 2011 - NEW PATIENT POPULATION
  
  
  • February 28, 2012 - PEDIATRIC EXCLUSIVITY
  
  

See also...

• Zemuron Consumer Information (Wolters Kluwer)
• Zemuron Consumer Information (Cerner Multum)
• Zemuron AHFS DI Monographs (ASHP)
• Rocuronium Consumer Information (Wolters Kluwer)
• Rocuronium Consumer Information (Cerner Multum)
• Rocuronium Bromide AHFS DI Monographs (ASHP)